Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
An antibody-drug conjugate targeting LGR5 effectively treats intestinal cancer in preclinical models.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, LGR5-targeted antibody–drug conjugates were demonstrated to induce cytotoxicity in LGR5-high gastrointestinal cancer cells and decrease tumor size and proliferation in colon cancer xenograft models [181,182].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [181]
Citations
Cites
Identification of stem cells in small intestine and colon by marker gene Lgr5
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007) · Nature · doi:10.1038/nature06196 · Cited by 5,687 · cited 3×
“These findings support previously published work indicating that Lgr5 cells continuously contribute to an established tumor mass in the setting of the Apc mutation (4, 5).”
BackgroundResultInfluentialaffy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
Crypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
A Dominant Mutation That Predisposes to Multiple Intestinal Neoplasia in the Mouse
Moser, A. R., Pitot, H. C., & Dove, W. F. (1990) · Science · doi:10.1126/science.2296722 · Cited by 1,591 · cited 2×
“To enable such a model, we combined the APCmin model of intestinal tumorigenesis with conditional mutant KrasG12D expression under the control of the intestinal specific VillinCre (7, 19, 20).”
MethodIn vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
Huch, M., Dorrell, C., Boj, S. F., van Es, J. H., Li, V. S. W., van de Wetering, M., Sato, T., Hamer, K., Sasaki, N., Finegold, M. J., et al. (2013) · Nature · doi:10.1038/nature11826 · Cited by 1,555 · cited 3×
“scencem agorg/ D ow nladed from shown to increase after liver damage and appear to participate in tissue repair (11).”
BackgroundResultInfluentialSite-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Self-citationA reserve stem cell population in small intestine renders Lgr5-positive cells dispensable
Tian, H., Biehs, B., Warming, S., Leong, K. G., Rangell, L., Klein, O. D., & de Sauvage, F. J. (2011) · Nature · doi:10.1038/nature10408 · Cited by 1,204
Cancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171
Cited by
Items 101–183 of 183
Zhou, J. W., Guo, Z., Yu, W., Li, S., & Qiao, W. (2019) · The American Surgeon · doi:10.1177/000313481908500418 · Cited by 19
Novel immunotherapeutics against LGR5 to target multiple cancer types
Chen, H., Mueller, N., Stott, K. M., Kapeni, C., Rivers, E., Sauer, C. M., Beke, F., Walsh, S. J., Ashman, N., O’Brien, L. M., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00121-2 · Cited by 21
“The killing activity of LGR5 scFv -CAR-T cells towards HEK293T cells expressing the cynomolgus LGR5-eGFP transgene was at approximately 85% of the killing potency against hLGR5-eGFP-expressing HEK293T cells likely due to the 2aa changes in the binding site (Fig.”
BackgroundMethodResultInfluentialMetrangolo, V., Blomquist, M. H., Dutta, A., Gårdsvoll, H., Krigslund, O., Nørregaard, K. S., Jürgensen, H. J., Ploug, M., Flick, M. J., Behrendt, N., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq0513 · Cited by 20
Greten, F. R. (2017) · Nature · doi:10.1038/543626a · Cited by 18
Yang, B., Zhou, J., Cai, K., Wang, Y., Feng, Y., Li, W., Jiang, Y., Kuo, S. H., Roy, J., Anorma, C., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302342120 · Cited by 20
Therapeutic Targeting of Gastrointestinal Cancer Stem Cells
Stem, J., Flickinger, J. C., Merlino, D. J., Caparosa, E. M., Snook, A. E., & Waldman, S. A. (2019) · Regenerative Medicine · doi:10.2217/rme-2018-0146 · Cited by 17
“Although there is much further work prior to therapies such as this being safe for use in human subject, this study did provide proof of concept that antibody–drug conjugates can be targeted at CSC surface markers [72].”
BackgroundGoto, N., Agudo, J., & Yilmaz, Ö. H. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.016 · Cited by 21
Targeting colorectal cancer (stem-like) cells using LGR5 directed antibody drug conjugates
Hirsch, D. D., & Ried, T. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.11.78 · Cited by 16
“In the manuscript entitled “Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer” and published in Science Translational Medicine (1), Junttila and colleagues report an interesting approach using antibody drug conjugates (ADCs) to target cells expressing the putative colorectal cance…”
BackgroundLi, F., Song, X., Li, X., Zhang, X., Feng, X., Wang, L., Xu, L., Luo, J., Zhu, B., Ren, W., et al. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.101916 · Cited by 15
Belling the “cat”: Wnt/β-catenin signaling and its significance in future cancer therapies
Goyal, A., Murkute, S. L., Bhowmik, S., Prasad, C. P., & Mohapatra, P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189195 · Cited by 19
Kim, J. K., Byun, M. R., Maeng, C. H., Kim, Y. R., & Choi, J. W. (2020) · Cancers · doi:10.3390/cancers12010203 · Cited by 14
“This was recently demonstrated via antibody–drug conjugates targeting Lgr5+ cells, which resulted in a reduction in tumor size, extended patient survival, and prevention of cancer recurrence [16,17].”
BackgroundStem Cells as Therapeutic Targets in Colorectal Cancer
Zalewski, A., Snook, A. E., & Waldman, S. A. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0099 · Cited by 15
Cui, J., Toh, Y., Park, S.-H., Yu, W., Tu, J., Wu, L., Li, L., Jacob, J., Pan, S., Carmon, K. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00395 · Cited by 17
Zhang, D., Tang, W., Niu, H., Tse, W., Ruan, H., Dolznig, H., Knösel, T., Karl-Heinz, F., Themanns, M., Wang, J., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.11.024 · Cited by 14
An, J., Hu, X., & Liu, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1114621 · Cited by 13
“In addition, LGR5-targeted ADCs were effective in the eradication of LGR5 gastrointestinal cancers and the suppression of tumor progression (87, 140).”
BackgroundTherapeutic Targeting of Tumor Cells Rich in LGR Stem Cell Receptors
Yu, S., Mulero, M. C., Chen, W., Shang, X., Tian, S., Watanabe, J., Watanabe, A., Vorberg, T., Wong, C., Gately, D. P., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00008 · Cited by 13
Self-citationRSPO3 Furin domain-conjugated liposomes for selective drug delivery to LGR5-high cells
van Kerkhof, P., Kralj, T., Spanevello, F., van Bloois, L., Jordens, I., van der Vaart, J., Jamieson, C., Merenda, A., Mastrobattista, E., & Maurice, M. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.025 · Cited by 11
Zhang, M., Fang, Y., Fu, X., Liu, J., Liu, Y., Zhu, Z., Ni, Y., Yao, M., Pan, Q., Cao, W., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6408 · Cited by 9
Microenvironmental cues in cancer stemness
Flanagan, D. J., Hodder, M. C., & Sansom, O. J. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0210-4 · Cited by 10
Molina-Peña, R., Tudón-Martínez, J. C., & Gutierrez, O. A. (2020) · Cancers · doi:10.3390/cancers12092590 · Cited by 10
“Moreover, recent findings on antibody-drug conjugates (ADC) showed that the targeting of Lgr5(+) colon CSCs with an ADC controlled the disease, but did not eliminate it, as observed in their reported growth curves [52].”
BackgroundYan, Y., Zhang, Y., Li, M., Zhang, Y., Zhang, X., Zhang, X., Xu, Y., Wei, W., Wang, J., Xu, X., et al. (2021) · Cancer Science · doi:10.1111/cas.15118 · Cited by 10
Tu, J., Toh, Y., Aldana, A. M., Wen, J. J., Wu, L., Jacob, J., Li, L., Pan, S., Carmon, K. S., & Liu, Q. J. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070943 · Cited by 10
Liu, F., Ai, F., Tang, A., Yang, Z., Li, Z., & Liu, S. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae212 · Cited by 12
Newly characterized motile sperm domain‐containing protein 2 promotes human breast cancer metastasis
Salem, Y., Yacov, N., Propheta‐Meiran, O., Breitbart, E., & Mendel, I. (2018) · International Journal of Cancer · doi:10.1002/ijc.31665 · Cited by 8
“MOSPD2 abundance was scored according to Junttila et al.15 who defined semi-quantitative IHC scores on a scale of 0–3, where 0 means no staining, 1 is weak, 2 is moderate and 3 is strong staining.”
MethodTargeting the root of colorectal cancer — eliminating cancer stem cells
Patman, G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.209 · Cited by 8
G Protein-coupled Receptors in Cancer Stem Cells
Jiang, Y., Zhuo, X., & Mao, C. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200305130009 · Cited by 8
Pagotto, S., Colorito, M. L., Nicotra, A., Apuzzo, T., Tinari, N., Protasi, F., Stassi, G., Visone, R., Franco, S. D., & Veronese, A. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00298-5 · Cited by 9
The intestinal stem cell as a target: A review
Faizo, N. L. (2024) · Medicine · doi:10.1097/md.0000000000039456 · Cited by 8
“[60] Zhang et al [61] reported that monomethyl aurista-tin E linked with anti-LGR5 antibody-forming antibody-drug conjugate may diminish colorectal cancer tumors.”
BackgroundHigh, P. C., Liang, Z., Guernsey-Biddle, C., Subramanian, S., Shyu, Y.-M., Aldana, A. M., Toh, Y., & Carmon, K. S. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102363 · Cited by 15
Advances in Proximity-Assisted Bioconjugation
Canzano, M., & Bernardes, G. J. L. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00368 · Cited by 8
Unveiling LGR5: Prostate cancer's hidden stem cell and treatment target
Patel, Y., & Prajapati, A. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.10.001 · Cited by 6
Temporal and Spatial Expression of LGR5 After Acute Spinal Cord Injury in Adult Rats
Chen, X., Hao, J., Fu, T., Liu, J., Yu, M., He, S., Qian, R., & Zhang, F. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1977-y · Cited by 6
Yamazaki, M., Kato, A., Oki, E., Zaitsu, Y., Kato, C., Nakano, K., Nakamura, M., Sakomura, T., Kawai, S., Fujii, E., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-0471-y · Cited by 6
Wong, C., Mulero, M. C., Barth, E. I., Wang, K., Shang, X., Tikle, S., Rice, C. E., Gately, D. P., & Howell, S. B. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001495 · Cited by 6
Tian, J., Zhang, L., La, X., An, Y., Fan, X., & Li, Z. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c03761 · Cited by 7
Chen, Z., Qi, H., Xue, Y., Zhang, Y., Zhang, Z., Xu, S., Liao, S., Zeng, X., Wu, J., Lv, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70015 · Cited by 7
Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions
Tiwatane, A. K., Khandave, P. Y., Kulkarni, S. S., Oisaki, K., & Pande, A. H. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01713-y · Cited by 7
“2 [92].”
Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells
Wang, W., Bai, L., Xu, D., Li, W., & Cui, J. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200504111914 · Cited by 7
Toh, Y., Wu, L., Tu, J., Liang, Z., Aldana, A. M., Wen, J. J., Li, L., Pan, S., Rowe, J. H., Hensel, M. E., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03121-2 · Cited by 8
LGR5: from stem cell marker to therapeutic target
High, P. C., Cappellino, M. G., Blackburn, T. A., & Carmon, K. S. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.02.006 · Cited by 5
Kim, J., Jeon, Y. J., Chang, I.-Y., Lee, J.-H., & You, H. J. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01381-1 · Cited by 4
Identification and Isolation of Human LGR5+ Cells Using an Antibody-Based Strategy
Dame, M. K., Huang, S., Attili, D., Spence, J. R., & Colacino, J. A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0747-3_1 · Cited by 5
LGR5 Modulates Differentiated Phenotypes of Chondrocytes Through PI3K/AKT Signaling Pathway
Wu, X., Fu, Y., Ma, J., Li, C., He, A., & Zhang, T. (2024) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-024-00645-1 · Cited by 4
“Through further exploration, LGR5 is now considered as a universal marker of stem cells in different tissues [24–26].”
Improving the Safety Profile of ADCs
Guffroy, M., Falahatpisheh, H., & Finkelstein, M. B. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9_3 · Cited by 7
Schmidt, B. J., Pan, C., Vezina, H. E., Sun, H., Leipold, D. D., & Gupta, M. (2016) · Wiley eBooks · doi:10.1002/9781119060727.ch9 · Cited by 4
(2024) · doi:10.21203/rs.3.rs-4446931/v1 · Cited by 4
Ruiz‐Malagón, A. J., Rodríguez‐Sojo, M. J., García-García, J., Ho‐Plagaro, A., García, F., Vezza, T., Redondo‐Cerezo, E., Griñán‐Lisón, C., Marchal, J. A., Rodríguez‐Cabezas, M. E., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01629-0 · Cited by 8
Clinical relevance of Lgr5 expression in colorectal cancer patients
Kim, Y., Kang, D. H., Song, G. J., Ahn, T. S., Son, M. W., Lee, M. S., & Baek, M. J. (2018) · Korean Journal of Clinical Oncology · doi:10.14216/kjco.18014 · Cited by 9
“These results are consistent with other studies, and result from the plasticity of CSCs and the maintenance of the CSCs pool by Lgr5- cells in primary tumors [27-29].”
ResultManipulating the murine Lgr5 locus using a rapid, efficient and flexible CRISPR/Cas9 pipelinePreprint
Reichmuth, J., Berg, J. V., Brügger, M. D., Hausmann, G., Valenta, T., & Basler, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.31.424946 · Cited by 3
“Accordingly, Lgr5 expression is often significantly upregulated in various subtypes of cancers and Lgr5 cancer stem cells contribute to tumour growth (Junttila et al., 2015; Gong et al., 2016; Cortina et al., 2017; Shimokawa et al., 2017).”
BackgroundSOX17 : a new therapeutic target for immune evasion of colorectal cancer
Das, A., Yilmaz, Ö. H., Yilmaz, O. H., & Deshpande, V. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-209878 · Cited by 2
Wang, H., Yan, X., Xia, C., Chen, D., Pan, B., Zhang, Y., & Zhang, Q. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1756741 · Cited by 3
Ansari, M. A., Abubakar, M., Ansari, M. M., Koya, N., Gupta, J., Aazam, M., Shinde, S. S., Ahmed, S., Rai, A., Murti, K., et al. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04906-9 · Cited by 2
Saito, S., Wuputra, K., Kato, K., & Yokoyama, K. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822231-7.00002-3 · Cited by 3
Oncogenic Role of Cancer Stem Cell LGR5 in Colorectal Cancer Progression
Kalkhajeh, S. G., Parsanezhad, A., Banoei, M., Vahidi, M., Kebria, M. M., Pezeshkian, Z., & Peyravian, N. (2021) · Canadian Journal of Medicine · doi:10.33844/cjm.2021.60609 · Cited by 3
Andel, D., Hagendoorn, J., Alsultan, A. A., Laclé, M. M., Smits, M. L. J., Braat, A. J. A. T., Kranenburg, O., Lam, M. G. E. H., & Rinkes, I. H. M. B. (2023) · HPB · doi:10.1016/j.hpb.2023.06.011 · Cited by 3
Epigenetic control of cell signalling in cancer stem cells
Joshi, G., & Basu, A. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.07.009 · Cited by 3
Insights from the bottom-up development of LGR5-targeting immunotherapeutics
Mueller, N., de la Roche, M., & de la Roche, M. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf017 · Cited by 2
“…cells over a 30-day treat-ment time course [44], while another, using the hu8E11v2 antibody demonstrated similar in vivo efficacy in targeting LoVo engrafted tumours [77]. hu8E11v2 was also used in a subsequent study in breast cancer and demonstrated reasonable efficacy in an in vivo tumour model.”
Lgr5-mediated restraint of β-catenin is essential for B-lymphopoiesis and leukemia-initiationPreprint
Cosgun, K. N., Robinson, M. E., Deb, G., Yang, X., Xiao, G., Sadras, T., Lee, J. W., Chan, L. N., Kume, K., Mangolini, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.12.989277 · Cited by 4
Self-citationCui, J., Park, S.-H., Yu, W., Carmon, K. S., & Liu, Q. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429956 · Cited by 2
“We first tested cytotoxic activity of R4Fu-Q65R-MMAE on HEK293T cells overexpressing LGR4, LGR5, or LGR6.”
BackgroundInfluentialPosey, T. A., Jacob, J., Parkhurst, A. N., Subramanian, S., Francisco, L. E., Liang, Z., & Carmon, K. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.01.482539 · Cited by 2
“Elimination of LGR5+ CSCs in CRC tumors using either genetic ablation approaches or LGR5-targeted antibody-drug conjugates (ADCs) resulted in tumor inhibition or stasis, with relapse after treatment termination (3,5,6,8).”
BackgroundElkoshi, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1704642 · Cited by 3
“This could be tested by treating healthy or disease-prone NOD mice with anti-LGR5 antibodies (148, 149) and assessing whether in fl ammatory diseases develop.”
Molecular analysis of tumor recurrence using established cancer stem cell-line and drug discovery
Nakano, K., Oki, E., Yamazaki, M., Suzuki, M., Kawai, S., Zaitsu, Y., Nishime, C., Ando, K., Nagae, G., Harimoto, N., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02948-2 · Cited by 1
Toh, Y., Tu, J., Wu, L., Aldana, A. M., Wen, J. J., Su, L., Yang, B. T., Liang, X., Li, L., Pan, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03826 · Cited by 1
Conti, S., Venturini, V., Cañellas-Socias, A., Cortina, C., Abenza, J. F., Attolini, C. S., Guerra, E. M., Xu, C. K., Li, J. H., Rossetti, L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.04.569244 · Cited by 1
High, P. C., Cappellino, M. G., Sullivan, S. P., Blackburn, T. A., Guernsey-Biddle, C., Liang, Z., & Carmon, K. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733843 · Cited by 1
Identifying and Targeting Cancer Stem Cells in Colorectal Cancer
Harnett, A. (2018) · Scholarship@Western (Western University) · Cited by 1
Rehman, S., Haynes, J., Lima‐Fernandes, E., Puri, A., Haller, A., Leung, C., Agro, L. A., Wang, Y., & O'Brien, C. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00007-3 · Cited by 2
Cancer Stem Cells in Patient Survival and Therapies in Cancer
Yang, Y., Tian, C., & Meng, W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5120-8_18
Abdiche, Y. N. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735560630.793560911
Wookey, P. J., Gupta, P., Hare, D. L., Ciccotosto, G. D., & Hutchings, C. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_261-1 · Cited by 2
Cancer Immunotherapies Targeting Cancer Stem Cells: Concepts, Applications, and Advances
Farhangnia, P., Shokri, M.-R., Akbarpour, M., & Delbandi, A. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_401
New modalities: Drugging the undruggable GPCR targets
Zawadzki, P., Graczyk, P. P., & Staroń, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00030-3
Wookey, P. J., Gupta, P., Hare, D. L., Ciccotosto, G. D., & Hutchings, C. J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_261
Petti, L., Rizzo, G., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433170
Petti, L., Rizzo, G., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433176
Petti, L., Rizzo, G., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433164
Petti, L., Rizzo, G., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433179
Petti, L., Rizzo, G., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433191
Petti, L., Rizzo, G., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433188
Petti, L., Rizzo, G., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433185
Tang, R., Liu, Q., Yang, J., Sun, M., Qin, J., Peng, Y., Jiang, H., Qiu, L., & Lin, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109874
CMS4-focused multi-omic integration enhances antigen target identification in colorectal cancerPreprint
Fox, E., Meunier, L., Weill, S., Appé, G., Behdenna, A., Hensen, L., Lafond, C., Nordor, A. V., & Marijon, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.04.722755
“…recovered established and investigational CRC antigens both at the CMS4-specific and at CRC-wide level, including LGR5, MET, and TACSTD2 (TROP2) (46–48) , supporting the robustness and translational validity of the discovery pipeline (see complete list of CMS4 well-established targets in Table S5).”
Development of LGR5-targeted antibody drugs and their prospects in tumor therapy
Zhang, T.-H., Tao, L. I., & Wei-Hong, T. A. O. (2026) · Shengming kexue · doi:10.3724/cbls.2026110
Metadata
- Authors
- Junttila, M. R., Mao, W., Wang, X., Wang, B.-E., Pham, T., Flygare, J., Yu, S.-F., Yee, S., Goldenberg, D., Fields, C., Eastham-Anderson, J., Singh, M., Vij, R., Hongo, J.-A., Firestein, R., Schutten, M., Flagella, K., Polakis, P., & Polson, A. G.
- Affiliations
- Genentech (US)
- Research and Early Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
- Corresponding author
- Junttila, Melissa R.
- Singh, Mallika
- Firestein, Ron
- Flagella, Kelly
- Polson, Andrew G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-11-18
- Volume
- 7
- Issue
- 314
- Pages
- 314ra186-314ra186
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2174197315
- Cited by
- 182
- References
- 32
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 19 · 2023: 17 · 2022: 7 · 2021: 23 · 2020: 19 · 2019: 20 · 2018: 24 · 2017: 13 · 2016: 10 · 2015: 1
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech Inc.
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- Lgr5, antibody-drug conjugates, colon cancer, cancer stem cells, tissue stem cells, targeted cancer therapy, G protein-coupled receptors, genetically engineered mouse models, intestinal tumorigenesis, tumor growth inhibition, drug safety
- MeSH terms
- Animals, Immunotoxins, Antineoplastic Agents, Colonic Neoplasms, Dose-Response Relationship, Drug, Feasibility Studies, Female, Male, Mice, Inbred C57BL, Mice, Nude, Mice, Transgenic, Time Factors, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Rats, Sprague-Dawley, Genes, APC, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.